



59th Scientific Conference of the
German-speaking Mycological
Society (DMyG) e. V.



© SeanPavonePhoto/ iStock.adobe

PROGRAMME

Myk2025

4–6 September | Cologne
www.dmykg-kongress.de

AmBisome®

STARK STARTEN

bei invasiven Mykosen



**A-Leitlinienempfehlung der AGIHO
bei Aspergillose – Candidose –
Mukormykoze in der First-Line¹**

AmBisome®
Liposomales Amphotericin B 50 mg



1. Ruhnke M et al. Onkopedia, Invasive Pilzinfektionen, Therapie, 2020.

AmBisome® liposomal 50 mg Pulver zur Herstellung einer Infusionsdispersion

Wirkstoff: Amphotericin B. **Zusammensetzung:** 1 Durchstechflasche mit 1,326 g Trockensubstanz enthält 50 mg in Liposomen verkapseltes Amphotericin B. Sonstige Bestandteile: Hydriertes (3-sn-Phosphatidyl)cholin (aus Sojabohnen), Cholesterol, Distearoylphosphatidylglycerol, all-rac- α -Tocopherol, Sucrose, Natriumsuccinat $6\text{ H}_2\text{O}$, Natriumhydroxid, Salzsäure. **Anwendungsgebiete:** Behandlung von schweren systemischen oder tiefen Mykosen. Empirische Behandlung von vermuteten Pilzinfektionen bei neutropenischen Patienten mit Fieber. Sekundärtherapie der viszeralen Leishmaniose (*Leishmania donovani*) bei immunkompetenten Patienten und bei Patienten mit geschädigtem Immunsystem. Bei Patienten mit geschädigtem Immunsystem muss mit Rezidiven gerechnet werden. Es liegen keine Erfahrungen zur Rezidivprophylaxe vor. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile, außer wenn der Zustand des Patienten lebensbedrohlich ist und ausschließlich durch AmBisome verbessert werden kann. Frühere schwere anaphylaktische oder anaphylaktoide Reaktion unter AmBisome. **Warnhinweise:** AmBisome ist nicht austauschbar mit anderen Amphotericin-B-haltigen Arzneimitteln. Enthält Sucrose (Zucker). **Nebenwirkungen:** Infusionsbedingte Nebenwirkungen klingen in der Regel nach Absetzen der Infusion rasch ab und treten möglicherweise nicht bei jeder weiteren Dosis erneut auf oder können ausbleiben, wenn die Infusion mit niedriger Infusionsrate (über zwei Stunden) verabreicht wird. Dennoch können schwere Infusionsreaktionen einen dauerhaften Abbruch der Therapie mit AmBisome erforderlich machen. **Sehr häufig ($\geq 1/10$):** Hypokaliämie, Übelkeit, Erbrechen, Schüttelfrost, Fieber. **Häufig ($\geq 1/100$ bis $< 1/10$):** Hyponatriämie, Hypokalziämie, Hypomagnesiämie, Hyperglykämie, Hyperkaliämie, Kopfschmerzen, Tachykardie, Hypotonie, Vasodilatation, Erröten (Flushing), Dyspnoe, Diarrhoe, Bauchschmerzen, auffällige Leberwerte, Hyperbilirubinämie, Erhöhung der alkalischen Phosphatase, Exanthem, Rückenschmerzen, Erhöhung des Kreatininwerts und des Blutharnstoffs, Brustschmerzen. **Gelegentlich ($\geq 1/1.000$ bis $< 1/100$):** Thrombozytopenie, anaphylaktoide Reaktionen, Konvulsionen, Bronchospasmus. **Häufigkeit nicht bekannt:** Anämie, anaphylaktische Reaktionen, Überempfindlichkeit, Herzstillstand, Arrhythmie, angioneurotisches Ödem, Rhabdomyolyse (assoziiert mit einer Hypokaliämie), Schmerzen der Skelettmuskulatur (beschrieben als Arthralgie oder Knochenschmerzen), Nierengversagen, Niereninsuffizienz. **Darreichungsform und Packungsgrößen:** Packungen mit 1 und 10 Durchstechflasche(n) mit Pulver zur Herstellung einer Infusionsdispersion. **Verschreibungspflichtig.** **Stand:** März 2024. **Pharmazeutischer Unternehmer:** GILEAD Sciences GmbH, 82152 Martinsried b. München

Programme overview	
Thursday, 4 September	4
Friday, 5 September	5
Saturday, 6 September	6
Organisation and imprint.....	7
Welcome notes	
by the conference chairs.....	8
by the chairman of the DMyKG	10
Invited speakers and keynote speakers.....	12
Scientific programme	
Thursday, 4 September	15
Friday, 5 September	20
Saturday, 6 September	26
Poster sessions	
Thursday, 4 September	32
Friday, 5 September	36
General information	39
Social programme.....	42
Sponsors and exhibitors.....	43
Media cooperations.....	45
Industrial symposia	46
Floor and exhibition plan.....	49
Index speakers, authors and chairs	51

[illegible]

PROGRAMME OVERVIEW | FRIDAY, 5 SEPTEMBER

Friday, 5 September					
Room 1-3	Room 4-5	Foyer (Upper floor)	Foyer (Ground floor)	Cologne Cathedral	
08:00–08:30					
Keynote Lecture II p. 20					
08:30–09:30					
Industrial Symposium II p. 47					
09:45–11:00	09:45–11:00				
Session 4 Advances in fungal diagnostics p. 20	Session 5 Dermatophytes and mucocutaneous infections p. 21				
11:15–12:15	11:15–13:00				
Industrial Symposium III p. 47	Wiley - Editorial Board Meeting NO PUBLIC MEETING! p. 23				
		12:15–13:30	12:15–12:45		
		Poster session II p. 34	Group photo p. 23		
13:30–14:30	13:30–14:30				
Joint Session - DMyKG w/ NVMY p. 23	Session 6 Host cell interaction and immune response p. 23				
14:30–15:30	14:30–15:30				
Session 7 Innovative antifungal therapies and drug development p. 24	Quiz Myc-Mania: A Quiz for Fungi Lovers p. 25				
15:45–16:45					
Industrial Symposium IV p. 47					
16:45–18:00					
DMyKG General Assembly p. 25					
				17:30–18:30	
				Guided tour I p. 25	
				18:30–19:30	
				Guided tour II p. 25	
				19:30–23:00 (Entry from 19:00)	
	Social evening at the Stapelhaus			S. 42	

Saturday, 6 September	
Room 1-3	Room 4-5
09:00–10:00 Industrial Symposium V p. 48	
10:15–11:30 Session 8 Emerging fungal threats and fungal outbreaks p. 26	10:15–11:30 Session 9 Fungal pathogenesis, biofilms and mycotoxins p. 27
11:45–13:00 Session 10 Host cell interaction and immune response p. 28	11:45–13:00 Session 11 Epidemiology and resistance mechanisms p. 29
13:00–13:15 Closing Ceremony p. 30	

Opening & Closing
Keynote Lectures
Scientific sessions
Industrial Symposium
ÖGMM Meetings
Poster sessions
Social programme
Other sessions
General Assembly

Venue

KOMED im MediaPark GmbH
Im MediaPark 7 | 50670 Cologne

Conference homepage

www.dmykg-kongress.de

Scientific organiser

German speaking Mycological Society (DMykG) e.V.



Conference chairs

Dr. Danila Seidel, PhD, FECMM

Prof. Dr. Oliver A. Cornely, FECMM

Dr. Rosanne Sprute, MD

CECAD Cluster of Excellence | University of Cologne | Institute for Translational Research

Scientific committee

Prof. Dr. Andreas Groll (Germany)

Prof. Dr. Birgit Willinger (Austria)

Dr. Blasius Liss (Germany)

Prof. Dr. Cornelia Lass-Flörl (Austria)

Prof. Dr. Cornelia Speth (Austria)

Dr. Danila Seidel (Germany)

Prof. Dr. David Denning (United Kingdom)

Dr. Ilana Reinhold (Germany)

Prof. Dr. Ilse D. Jacobsen (Germany)

Dr. Jannik Stemler (Germany)

Dr. Jacques Meis (Netherlands)

Prof. Dr. Jean-Pierre Gangneux (France)

Dr. Jon Salmanton-García (Germany)

Prof. Dr. Jörg Steinmann (Germany)

Dr. Jürgen Prattes (Austria)

Dr. Laura Walti (Switzerland)

Prof. Dr. Maricela Valerio (Spain)

Prof. Dr. Martin Hönigl (Austria)

Prof. Dr. Michaela Lackner (Austria)

Prof. Dr. Oliver A. Cornely (Germany)

Prof. Dr. Oliver Kurzai (Germany)

Dr. Rosanne Sprute (Germany)

Prof. Dr. Salomé LeibundGut-Landmann (Switzerland)

Dr. Sarina Butzer (Germany)

Dr. Sebastian Wurster (USA)

Dr. Silke Uhrlaß (Germany)

Prof. Dr. Sven Krappmann (Germany)

Dr. Tamara Rügamer (Germany)

Prof. Dr. Thomas Lehrnbecher (Germany)

Prof. Dr. Zoi-Dorothea Pana (Cyprus)

Professional conference organiser

Conventus Congressmanagement & Marketing GmbH

Ms Jessica Kolb | Tel. +49 3641 31 16-341

dmykg-conference@conventus.de | www.conventus.de



Programme creation

Layout

Print

Edition

Editorial deadline

Conventus Congressmanagement & Marketing GmbH

printworld.com GmbH | Messering 5 | 01067 Dresden

200

20 August 2025



Dear Esteemed Colleagues,

It is our great honor and pleasure to welcome you to the MYK 2025 – the 59th Scientific Conference of the German-speaking Mycological Society (DMyKG), taking place from 4 to 6 September 2025 in Cologne.

This year's meeting is dedicated to a broad spectrum of timely topics in medical mycology. The scientific program spans from the application of artificial intelligence in the diagnosis of fungal infections, strategies for preventing biofilm formation, the implementation of personalized prophylactic measures, to the development of innovative therapeutic approaches, including pipeline antifungal compounds and immunotherapies – with special consideration for pediatric patients. Emerging trends in antifungal resistance and current strategies to control *Candida auris* will also be addressed in depth. With this, MYK 2025 offers a comprehensive overview in medical mycology – from molecular mechanisms to real-world clinical practice.

Highlights of the program include keynote lectures by the internationally renowned experts Arnaldo Colombo (São Paulo, Brazil), Arunaloke Chakrabarti (Chandigarh, India), and Ferry Hagen (Nijmegen, the Netherlands). The joint symposium hosted by the DMyKG and the Netherlands Society for Medical Mycology (NVMM) will further enrich the program by offering critical insights into recent developments in medical mycology with the focus on *C. auris*.

We are grateful for the generous support of our industry partners, which has enabled the inclusion of dedicated symposia developed in collaboration with Basilea, Gilead, Mundipharma, Pfizer, and Shionogi. These sessions will highlight innovative, practice-oriented approaches to diagnostics and treatment in adult and pediatric patients.

Beyond the scientific program, we are pleased to offer a range of networking opportunities: a guided tour "On the Roofs of Cologne Cathedral" and a walk "Beneath the Cathedral" will provide new perspectives on Cologne's most iconic landmark. The conference dinner will take place in a traditional Cologne brewhouse located on the banks of the River Rhine, where participants will have the opportunity to meet this year's award recipients in an informal and convivial setting.

We would like to express our sincere gratitude to the Scientific Committee, all contributors and speakers, our industry partners, and the organizing team at Conventus for their outstanding commitment and support.

WELCOME NOTE BY THE CONFERENCE CHAIRS

We wish you an inspiring conference filled with new insights, fruitful discussions, and valuable connections here at MYK25 in Cologne!

With kind regards,

Danila Seidel, Oliver A. Cornely, and Rosanne Sprute
Conference Chairs, German-speaking Mycological Society (DMyKG)





Dear Colleagues and Friends,

It is my great pleasure to warmly welcome you all to MYK2025 in Cologne!

We can look forward to a dynamic and engaging exchange on the latest developments in medical mycology and cutting-edge research on pathogenic fungi and fungal infections. This year's outstanding program will spotlight the ongoing rise in fungal infections, the emergence of new fungal pathogens, and the growing challenge of resistance. At the same time, we will hear about promising new antifungal drugs—some first-in-class, others representing significant advancements of existing therapies—that have either been recently approved or are in the final stages of clinical development. I am confident that MYK2025 will provide new insights for all of us.


This year's meeting takes place at the heart of clinical mycology in Germany: The Cologne ECMM Excellence Center for Invasive Fungal Infections has long been an internationally respected hub for invasive fungal infections. I would like to express my sincere gratitude to the local organizing team—Danila Seidel, Rosanne Sprute, and Oliver Cornely—for their dedication and effort in bringing this exciting program to life. For Oliver, who already organized the MYK2009, this marks his second MYK presidency. Back then, he served as President of our society, the DMyKG. Today, he is President-elect of the International Society for Human and Animal Mycology (ISHAM)—a reflection of both his personal achievements and the international impact of the Cologne team.

Besides highlighting work from our mycological community, this years' meeting engages highly renowned international keynote speakers and a joint symposium with our Dutch colleagues and the Nederlandse Vereniging voor Medische Mycologie. I personally look forward to inspiring sessions, fruitful discussions, and reconnecting with colleagues and friends.

Welcome to MYK2025!

Prof. Oliver Kurzai, M.D.

President, German-speaking Mycological Society (DMyKG)



SHIONOGI

Besuchen Sie unser Symposium:

Invasive Pilzinfektionen heute und morgen – Herausforderungen und Ausblick

05.09.2025 | 08:30-09:30 Uhr

**Innovationen
seit 1878**

INVITED SPEAKERS AND KEYNOTE SPEAKERS

Keynote speakers

Prof. Dr. Arnaldo Lopes Colombo

Federal University of São Paulo-UNIFESP



Prof. Dr. Arunaloke Chakrabarti

Doodhadhari Burfani Hospital



Invited speakers

Dr. Alexander Aldejohann

University Hospital Würzburg



Prof. Dr. Amanda Ribeiro dos Santos

University of São Paulo



Prof. Dr. Amir Seyedmousavi

National Institutes of Health / Clinical Center



Prof. Dr. Andrew Ullmann*

German Federal Parliament / University Hospital Würzburg



Prof. Dr. Birgit Willinger

Medical University of Vienna



Prof. Dr. Daniele Roberto Giacobbe

University of Genoa



Prof. Dr. David Denning

University of Manchester



Prof. Dr. Jean-Pierre Gangneux

Rennes Teaching Hospital



Prof. Dr. Jörg Steinmann

Hospital Nürnberg



*Prof. Dr. Andrew Ullmann, MdB | commons.wikimedia. by licence 4.0

Invited speakers

Prof. Dr. Joost Wauters

KU Leuven – University of Leuven



Prof. Dr. Kai Dallmeier

KU Leuven – University of Leuven



Dr. med. Laura Naëmi Walti

Inselspital, University Hospital Bern



Prof. Dr. Maricela Valerio Minero

Hospital General Universitario Gregorio Marañón



Dr. Mark Gresnigt

Leibniz Institute for Natural Product Research and Infection Biology



Prof. Dr. Michaela Lackner

Medical University of Innsbruck



Prof. Dr. Oliver Kurzai

University of Würzburg



Dr. Sebastian Wurster

The University of Texas MD Anderson Cancer Center



Prof. Dr. Shivaprakash Rudramurthy

Postgraduate Institute Of Medical Education And Research



Prof. Dr. Subhra Kumar Biswas

Ignaz-Semmelweis-Institute and Medical University of Graz



Prof. Dr. Zoi-Dorothea Pana

University of Nicosia (UNIC) / Medical School





10:30–12:00 ÖGMM Board Meeting

Room 4-5

12:00–12:45 Opening Ceremony

Room 1-3

12:00 Welcome note by the conference chairs

Oliver A. Cornely, Danila Seidel, Rosanne Sprute (Köln/DE)

12:15 Award of the “Forschungsförderpreis der DMykG”

12:20 “Forschungsförderpreis der DMykG” – Lecture by the award winner

12:30 Dem Pionier der medizinischen Mykologie Friedrich Staib zum
100. Geburtstag

Barbara Buchberger (Berlin, Essen/DE), Volker Rickerts (Berlin/DE)



12:45–13:15 Keynote Lecture I

Room 1-3

Chair Ilse D. Jacobsen (Jena/DE)



12:45 KL-I

Invasive Fungal Infections: From Local Epidemiology to Global Strategies
Arunaloke Chakrabarti (Haridwar/IN)

13:30–14:45 Session 1 – Host cell interaction and immune response

Room 1-3

Chairs Sven Krappmann (Erlangen/DE), Amanda Ribeiro dos Santos (São Paulo/BR)



13:30 S1-01

Macrophages plasticity, trained immunity and their implications in fungal
infection

Subhra Kumar Biswas (Graz/AT)

13:50 S1-02

Comparison of the human fungal pathogenic fungi *Aspergillus fumigatus*
and *Lichtheimia corymbifera* regarding the interaction with macrophages
Franziska Schmidt, Rasha Zaher, Isabel Heineking, Thorsten Heineking,
Axel A. Brakhage (Jena/DE)

- 14:05 **S1-03**
Using human airway and alveolar organoid-derived monolayers to quantify parameters of early cryptococcal infections
Sebastian Reusch, Emily Korsch, Jumana Ibrahim-Bacha, Charlotte Schwister, Anton Aebischer, Christian Klotz, Volker Rickerts (Berlin/DE)
- 14:15 **S1-04**
Comparative analysis of the role of reactive oxygen intermediate deficiency in host responses to *Candida albicans* and *Aspergillus fumigatus*
Aia Shehata (Jena/DE), Kerstin Hünigier-Ast (Würzburg/DE), Franziska Schmidt, Olaf Knemeyer (Jena/DE), Thierry Fontaine, Vishukumar Aimaniananda (Paris/FR), Axel A. Brakhage (Jena/DE), Oliver Kurzai, (Würzburg, Jena/DE)
- 14:25 **S1-05**
New perspectives on antifungal immunotherapy
Sebastian Wurster (Houston, TX/US)
- 13:30–14:45 **Session 2 – Innovative antifungal therapies and drug development** 
Room 4-5
Chairs Daniele Roberto Giacobbe (Genoa/IT), Thomas Orasch (Jena/DE)
- 13:30 **S2-01**
Innovative anti-infectives and the AMNOG benefit assessment: From barriers to incentives – A shift in Evaluation Policy? A template for Europe?
Andrew John Ullmann (Würzburg/DE)
- 13:45 **S2-02**
Resistance challenges in emerging fungi and therapeutic innovation in high-burden settings
Shivaprakash Rudramurthy (Chandigarh/IN)
- 13:55 **S2-03**
Non-fumigatus *Aspergillus* species in clinical practice: Diagnostic and therapeutic implications
Amir Seyedmousavi (Bethesda, MD/US)
- 14:10 **S2-04**
Establishment of an advanced cell culture model for investigation of antifungal drug delivery applications
Derya Nur Cömert, Sophie Dietz, Antje Meyer, Thomas Orasch (Jena/DE)

14:20 **S2-05**
A new approach to tackle infectious diseases of *Aspergillus* species using programmable cytotoxic nucleases
Rebecca Heger, Christian Zurek, Torsten Fauth, Paul Scholz (Zwingenberg/DE)

14:30 **S2-06**
Therapeutic drug monitoring of midostaurin and posaconazole to determine drug interactions in FLT3-mutated acute myeloid leukemia
Carolin Joisten, Sibylle Mellinghoff, Danila Seidel, Carsten Müller, Charlotte Müller-Ohrem, Karl-Anton Kreuzer, Lukas Frenzel, Michael Hallek, Philipp Köhler, Oliver A. Cornely, Jannik Stemler (Köln/DE)

14:40 **S2-07**
A novel complement-based antifungal therapy targeting clinically relevant molds
Verena Harpf (Innsbruck/AT, Copenhagen/DK), Cornelia Speth, Günter Rambach, Verena Fleischer (Innsbruck/AT), Mikkel-Ole Skjødtt (Copenhagen/DK), Reinhard Würzner (Innsbruck/AT), Peter Garred, Anne Rosbjerg (Copenhagen/DK)

15:15–16:15 **Industrial Symposium I**
see page 46



16:15–17:15 **Lightning talk & Poster Preview**



Room 1-3

Chairs Danila Seidel (Köln/DE), Rosanne Sprute (Köln/DE)

16:15 **LT-01**
Comparison of two Commercial Realtime PCR Assays for the Detection of *Aspergillus*-DNA
Dirk Schmidt, Hedda L. Verhasselt, Laura-Isabel Korth, Andrea Hain, Jan Buer, Peter-Michael Rath (Essen/DE)

16:20 **LT-02**
A PCR-based approach for the detection of dermatophytes: Insights from real-life clinical data
Stephan Steixner, Stefan Fuchs, Roya Vahedi-Shahandashti, Cornelia Lass-Flörl (Innsbruck/AT)

- 16:25 **LT-03**
NFDI4Microbiota supporting microbiology research providing data access, services, training and workflows
Lina Junctorius, Konrad U. Förstner (Köln/DE),
Alice C. McHardy (Braunschweig/DE)
- 16:30 **LT-04**
Elucidating the contribution of Ugp1 in *Aspergillus fumigatus* 5-fluorocytosine activity
Lukas Birštonas, Fabio Gsaller, Alexander Kühbacher (Innsbruck/AT)
- 16:35 **LT-05**
Antifungal tolerance – the ability of fungi to make therapy difficult
Katarzyna Góralska, Małgorzata Szybka, Filip Karuga,
Dorota Pastuszek-Lewandoska, Ewa Brzezińska-Lasota (Łódź/PL)
- 16:40 **LT-06**
Detecting tolerance in non-*albicans* *Candida* species from blood culture – a pilot for the ECMM-Candida IV study
Katharina Rosam, Roya Vahedi-Shahandashti (Innsbruck/AT),
Stella Wolfgruber (Graz/AT), Oliver A. Cornely (Köln/DE), Martin Hönigl (Graz/AT),
Cornelia Lass-Flörl (Innsbruck/AT)
- 16:45 **LT-07**
Employing human *in vitro* macrophage models to identify early immune response mediators against *Aspergillus fumigatus*
Jeany Söhnlein (Würzburg/DE), Sascha Schäuble (Jena/DE),
Zahraa Abboud (Würzburg/DE), Kerstin Hünninger-Ast (Jena/DE), Michelle Seif,
Hermann Einsele, Andreas Beilhack, Jürgen Löffler (Würzburg/DE)
- 16:50 **LT-08**
Responses of human monocytes to co-infection with *Candida albicans* and *Staphylococcus aureus*
Gabriel Braune, Natalie Nieuwenhuizen (Würzburg/DE),
Kerstin Hünninger-Ast (Jena/DE), Knut Ohlsen (Würzburg/DE),
Oliver Kurzai (Würzburg, Jena/DE)
- 16:55 **LT-09**
Intracellular survival of *Lichtheimia corymbifera* in macrophages
Rasha Zaher, Franziska Schmidt, Thorsten Heinekamp,
Axel A. Brakhage (Jena/DE)

- 17:00 **LT-11**
Establishment of a molecular system to assess RNA-DNA triple helix formation in *Aspergillus fumigatus*
Valentina Lazarova, Laura Fabre, Akanksha Mourya, Amelia E. Barber, Holger Bierhoff, Matthew Blango (Jena/DE)
- 17:05 **LT-12**
Cytostatic drugs against Pancreatic Ductal Adenocarcinoma (PDAC) can cross-affect the viability of the pro-carcinogenic yeast *Malassezia globosa*
Sophie Mühlmann, Fabienne Nocera, Arno Amann, Manuel Maglione, Nadia Parth, Cornelia Speth, Günter Rambach (Innsbruck/AT)
- 17:10 **LT-13**
Diversity of pathogenic *Fusarium* species in outdoor environment
Leif Lammers, Grit Walther, Enrico Garbe, Slavica Janevska (Jena/DE)
- 16:15–17:15 Session 3 – Pediatric fungal infection** 
- Room 4-5
- Chairs Thomas Lehrnbecher (Frankfurt a. M./DE), Sarina Butzer (Köln/DE)
- 16:15 **S3-01**
Update on new antifungal drugs in paediatrics
Zoi-Dorothea Pana (Nikosia/CY)
- 16:30 **S3-02**
Yeast in Pediatric Leukemia
Andreas Groll (Münster/DE)
- 16:45 **S3-03**
Molds in Pediatric Leukemia
Konrad Bochennek (Frankfurt a. M./DE)
- 17:00 **S3-04**
Yeast infections in neonates
Sarina Butzer (Köln/DE)
- 17:15-18:45 Poster session I**
see page 32
- 18:00-18:45 ÖGMM General Assembly**
- Room 4-5
- 18:30-20:00 Welcome reception**
see page 42

08:00–08:30 Keynote Lecture II

Room

1-3

Chair

Oliver A. Cornely (Köln/DE)



08:00

KL-II

Treatment decision-making in Candidemia: The Science and The Art
 Arnaldo Lopes Colombo (São Paulo/BR)

08:30–09:30 Industrial Symposium II

see page 47

**09:45–11:00 Session 4 – Advances in fungal diagnostics**

Room

Room 1-3

Chairs

Cornelia Lass-Flörl (Innsbruck/AT), Tamara Rügamer (Köln/DE)



09:45

S4-01

False-positive galactomannan values in bronchoalveolar lavage fluid are significantly more common in critically ill patients after aspiration
 Karl Bihlmaier, Laura Vonbrunn, Richard Strauß, Kosmas Macha, Reinhard Schneider, Larissa Herbst, Carsten Willam, Mario Schiffer, Christian Bogdan, Jürgen Held (Erlangen/DE)

09:55

S4-02

Mucorales PCR testing in bronchoalveolar lavage fluid samples:
 a prospective cohort study
Jürgen Prattes, Karl Dichtl, Sarah Sedik, Ulrike Glatz, Matthias Egger, Albert Wölfler, Paul Zajic, Harald Kessler, Martin Hönigl (Graz/AT)

10:05

S4-03

Sequential serum galactomannan as response marker for invasive aspergillosis – an exploratory study from the FungiScope© registry
Christina Többen, Oliver A. Cornely, Carolin Joisten (Köln/DE), José A. Cozzi (Rosario/AR), Baptiste Hoellinger (Strasbourg/FR), Deniz Yılmaz Karapinar (Bornova/TR), Daniel Richter (Heidelberg/DE), Andreas Groll (Münster/DE), Gustavo A. Méndez (Posadas/AR), Jeffrey D. Jenks (Durham, NC/US), Nurettin Erben (Eskişehir/TR), Leyre López Soria (Barakaldo/ES), Philipp Köhler (Köln/DE), Anna Apostolopoulou (Boston, MA, New York, NY/US), Dries Deeren (Roeselare/BE), Rika Draenert (Munich/DE), Iker Falces-Romero (Madrid/ES), Julio Maquera-Afaray (Lima/PE), Lisa Meintker (Erlangen/DE), Ruwanthi Kolamunnage-Dona (Liverpool/GB), Danila Seidel, Jannik Stemler (Köln/DE)

- 10:15 **S4-04**
Diagnostic accuracy of PCR assays for mucormycosis: A systematic review and meta-analysis
Michaela Lackner (Innsbruck/AT)
- 10:25 **S4-05**
CandEYE – Serial non-mydriatic fundoscopy in patients with candidemia
Ilana Reinhold, Lebriz Altay, Anna Lentzsch, Jon Salmanton-García, Emilie Makcevic, Claus Cursiefen, Oliver A. Cornely, Rosanne Sprute (Köln/DE)
- 10:35 **S4-06**
Development of a point-of-care DNA extraction for the detection of fungal DNA from diverse sample types such as hair, nails, skin or liquids
Johannes Graf, Andy Wende (Hallbergmoos/DE)
- 10:40 **S4-07**
ImmunoPET and LSM-based imaging for early diagnosis of invasive Aspergillosis using Fc-modified anti-*Aspergillus fumigatus* antibodies
Sophie Tonneau (Tübingen/DE), Lea Allerchen (Essen/DE)
- 10:45 **S4-08**
Image processing algorithms to differentiate the extent of *in vitro* infections with *Tricho Phyton rubrum* on bovine hoof sheets
Udo Bock (Tawern/DE), Dirk Neumann (Kleinblittersdorf/DE)
- 10:50 **S4-09**
Improving *Talaromyces marneffe* diagnostics via a mitochondrial-targeting qPCR and isothermal reaction-based lateral flow assay (LAMP-LFA)
Wessel van de Sande (Utrecht/NL), Ratna Mohd-Tap (Selangor/MY), Jose Guillermo Pereira Brunelli (Asuncion/PY), Jos Houbraken (Utrecht/NL), Ferry Hagen (Utrecht, Amsterdam/NL)
- 09:45–11:00 **Session 5 – Dermatophytes and mucocutaneous infections** 
Room 4-5
Chairs Silke Uhrlaß (Rötha OT Mölbis/DE), Volker Rickerts (Berlin/DE)
- 09:45 **S5-01**
Rare keratinophilic fungi – potentially harmful and on the brink of pathogenicity?
Jochen Brasch (Kiel/DE)

- 10:00 **S5-02**
Azole-resistant *Trichophyton rubrum* isolates exhibit *Erg11B Gly443Cys* substitutions comparable to *T. indotineae* mutants but no genomic amplification of *Erg11B*
Anke Burmester, Luisa Krauß, Jörg Tittelbach (Jena/DE), Pietro Nenoff (Mölbis/DE), Mario Fabri, Cornelia Wiegand (Jena/DE)
- 10:10 **S5-03**
Isolation of *Histoplasma capsulatum* from wild and domestic animals in Germany
Jasmin Gerkrath, Ilka Mc Cormick Smith, Theresa Störiko (Berlin/DE), Michael Suntz (Freiburg i. Br./DE), Ursula Mayer (Kornwestheim/DE), Almuth Klatt, Woelki Tobias, Simon H. Tausch, Volker Rickerts (Berlin/DE)
- 10:20 **S5-04**
Dynamic gene expression and functional networks underlying spore germination in *Microsporum*
Xin Zhou (Nijmegen/NL), Peiying Feng (Guangzhou/CN), Sybren de Hoog (Nijmegen/NL)
- 10:30 **S5-05**
Novel, fast and cost-effective real-time PCR based method for the differential diagnosis of Dermatophytes in veterinary medicine
Varsha Garg (Berlin/DE), Rainer Söller (Hamburg/DE), Andy Wende, Johannes Graf (Hallbergmoos/DE), Yvonne Gräser (Berlin/DE)
- 10:40 **S5-06**
Molecular epidemiology of the “forgotten” dermatophyte *Microsporum ferrugineum* in Germany – now also detected as a double infection with *Trichophyton tonsurans* in wrestlers
Silke Uhrlaß (Rötha OT Mölbis/DE), Claudia Baldauf, Oliver Hirschsteiner (Bad Reichenhall/DE), Konstantin Dumann (Taucha/DE), Daniela Koch, Hanna Muetze, Constanze Krueger (Rötha OT Mölbis/DE), Uwe Paasch (Taucha/DE), Pietro Nenoff (Rötha OT Mölbis/DE)

11:15–12:15 Industrial Symposium III
see page 47



11:15–13:00 Wiley- Editorial Board Meeting – **No public meeting!**
Room Room 4-5



12:15–13:30 Posters session II
see page 34

12:15–12:45 Group photo
Room Foyer (Ground floor)

13:30–14:30 Joint Session- DMykG w/ NVMY – *Candida auris*: Is search and
destroy the answer?
Room 1-3
Chairs Birgit Willinger (Wien/AT), Jacques Meis (Nijmegen/NL)



13:30 The Dutch approach
Jacques Meis (Nijmegen/NL)

13:45 The German defence
Oliver Kurzai (Würzburg/DE)

14:00 The Austrian experience
Birgit Willinger (Wien/AT)

14:15 Discussion

13:30–14:30 Session 6 – Host cell interaction and immune response
Room 4-5
Chairs Ilse D. Jacobsen (Jena/DE), Laura Seldeslachts (Leuven/BE)



13:30 S6-01
Dysregulated inflammatory responses of (recurrent) vulvovaginal
candidiasis
Mark Gresnigt (Jena/DE)

13:50 S6-02
Role of Chitin sensing in the immune regulation of human Keratinocytes
responding to fungal infections
Carlotta Imelmann, Tobias Obser, Judith B. Staudenmeyer,
Sabine Vidal-y-Sy, Christian Gorzelanny (Hamburg/DE)

- 14:00 **S6-03**
Role of mitochondrial dynamics in fungal pathogen-driven host defense
Isabel Heineking, Axel A. Brakhage, Franziska Schmidt, Leijie Jia (Jena/DE)
- 14:10 **S6-04**
Candida albicans-epithelial interactions at the CNS barriers
Stanislaw Schmidt (Frankfurt a. M./DE), Christian Schwerk, Horst Schroten (Mannheim/DE), Hiroshi Ishikawa (Tsukuba/JP), Björn Häupl, Thomas Lehrnbecher, Henriette Rudolph (Frankfurt a. M./DE)
- 14:20 **S6-05**
Role of neutrophil-derived extracellular vesicles in supporting *Candida albicans* escape from immune phagocytosis
Jennifer Patitz, Natalie Nieuwenhuizen (Würzburg/DE), Thomas Krüger, Anastasia Solomatina, Yann Bachelot, Ann-Kathrin Zimmermann, Matthew Blango, Olaf Kniemeyer, Axel A. Brakhage, Marc-Thilo Figge (Jena/DE), Oliver Kurzai, Kerstin Hünninger-Ast (Würzburg, Jena/DE)
- 14:25 **S6-06**
Immunology of *Malassezia* in pancreatic cancer: Role of complement and fungal surface modifications by pancreatic enzymes
Dina Aly, Günter Rambach, Nadia Parth, Magdalena Neurauter, Manuel Maglione, Cornelia Speth (Innsbruck/AT)
- 14:30–15:30 **Session 7 – Innovative antifungal therapies and drug development** 
Room 1-3
Chairs Laura N. Walti (Bern/CH), Christina Bahrs (Wien/AT)
- 14:30 **S7-01**
Transforming mycology: How AI enhances fungal disease management
Daniele Roberto Giacobbe (Genoa/IT)
- 14:45 **S7-02**
Implementing personalized antifungal prophylaxis strategies in patients at risk for fungal infections
Maricela Valerio Minero (Madrid/ES)
- 15:00 **S7-03**
VAPA: from bed to bench and back
Joost Wauters (Leuven/BE)

15:15 [S7-04](#)
 Toward Shorter Therapy for Candidemia in Adults: Defining Uncomplicated Candidemia
 Ilana Reinhold (Köln/DE), Susanne Picardi (Heidelberg/DE),
 Blasius Liss (Wuppertal/DE), Danila Seidel, Jannik Stemler, Philipp Köhler,
 Tamara Rügamer, Rosanne Sprute, Oliver A. Cornely (Köln/DE)

15:25 [S7-05](#)
 Macromolecular prodrugs to treat intracellular persisting fungal pathogens
Thomas Orasch, Julien Alex, Katherin Gonzalez, Gauri Gangapurwala,
 Antje Vollrath, Melanie Händel, Nicole Roesner, Zoltán Cseresnyés,
 Maira Rosin, Christine Weber, Stephanie Hoepfener, Thorsten Heinekamp,
 Carlos Guerrero-Sánchez, Marc-Thilo Figge, Ulrich S. Schubert,
 Axel A. Brakhage (Jena/DE)

14:30–15:30 [Quiz – Myco-Mania: A Quiz for Fungi Lovers](#)
 Room 4-5
 Chairs David Denning (Manchester/GB), Cornelia Lass-Flörl (Innsbruck/AT)



15:45–16:45 [Industrial Symposium IV](#)
 see page 47



16:45–18:00 [DMykG General Assembly](#)
 Room 1-3



17:30–19:30 [Guided tours](#)
 Cologne Cathedral

19:30–23:00 [Social evening](#) (see page 42)
 Place Stapelhaus Köln (Frankenwerft 35 | 50667 Cologne)



09:00–10:00 Industrial Symposium V
see page 48



10:15–11:30 Session 8 – Emerging fungal threats and fungal outbreaks
Room 1-3
Chairs Subhra Kumar Biswas (Graz/AT), Jean-Pierre Gangneux (Rennes/FR)



10:15 S8-01
The invisible threat: Strategies for monitoring environmental fungal load in healthcare settings
Jean-Pierre Gangneux (Rennes/FR)

10:30 S8-02
Optimizing surveillance and management of pulmonary aspergillosis in solid organ transplant recipients
Laura N. Walti (Bern/CH)

10:45 S8-03
Public health mycology – where next
David Denning (Manchester/GB)

11:00 S8-04
Differential susceptibility of five *Candida auris* clades against surface disinfection
Arthur Lang (Nürnberg/DE), Henrik Gabriel, Toni L. Meister (Hamburg/DE), Jacques Meis (Nijmegen/NL), Eike Steinmann (Bochum/DE), Florian H.H. Brill (Hamburg/DE), Jörg Steinmann (Nürnberg/DE)

11:10 S8-05
Candida auris in Austria: Repeated introductions from abroad based on epidemiological and phylogenetic data
Kathrin Spettel, Felix Lötsch, Richard Kriz, Madita Loy, Birgit Willinger (Wien/AT)

11:18 S8-06
Current trends on antifungal prophylaxis in solid organ transplantation
Jon Salmanton-García (Köln/DE), Alessandro Giacinta (Madrid/ES), Maddalena Giannella (Bologna/IT), Antonio Vena (Genoa/IT), Patricia Muñoz (Madrid/ES), Oliver A. Cornely (Köln/DE), Maricela Valerio Minero (Madrid/ES)



10:15–11:30 Session 9 – Fungal pathogenesis, biofilms and mycotoxins

Room

4-5

Chairs

Jürgen Prattes (Graz/AT), Maricela Valerio Minero (Madrid/ES)

10:15

S9-01

Investigation of *Aspergillus fumigatus* small RNA biogenesis uncovers evidence of double-stranded RNA-dependent growth arrest
Xiaoqing Pan, Abdulrahman Kelani, Matthew Blango (Jena/DE)

10:25

S9-02

Presence of endosymbiont bacteria in clinical strains of *Rhizopus microsporus*
Antonio Uribe Munoz (Würzburg/DE), Grit Walther (Jena/DE), Ronny Martin, Oliver Kurzai (Würzburg, Jena/DE)

10:30

S9-03

Candida albicans strain diversity: Impact on colonisation and host responses
 Sayoni Chakraborti, Ketema A. Merga, Ilse D. Jacobsen (Jena/DE)

10:45

S9-04

Virulence of *Aspergillus* section *Flavi* using the *Galleria mellonella* model
Shaoqin Zhou (Nijmegen/NL, Guiyang/CN), Shereen O. Abd Algaffar (Omdurman/SD), Mawahib A. I. Ismail (Khartoum/SD), Henrich van der Lee (Nijmegen/NL), Yingqian Kang (Guiyang/CN), Sybren de Hoog (Nijmegen, Hilversum/NL), Sarah A. Ahmed (Nijmegen, Hilversum/NL, Kuwait/KW)

10:55

S9-05

Unraveling the pathogenicity of the *Candida parapsilosis* species complex through comparative pan-genomic analysis
Yuanyuan Tang (Jena/DE, Shenzhen/CN), Yating Ning (Beijing/CN), Geraldine Butler (Dublin/IE), Li Zhang (Beijing/CN), Amelia E. Barber (Jena/DE), Bing Zhai (Shenzhen/CN)

11:05

S9-06

Detection of the yeast *Malassezia* in pancreatic cancer tissue correlates with grading and staging of the tumor
Cornelia Speth, Ruben Bellotti, Gudrun Thurner, Georg Schäfer, Glory Ranches (Innsbruck/AT), Tamas Nemeth, Lili Balogh (Budapest/HU), Günter Rambach, Manuel Maglione (Innsbruck/AT)

11:15	S9-07 Experimental platforms of medical device-related biofilms and anti-biofilm strategies Jörg Steinmann (Nürnberg/DE)	
11:45–13:00	Session 10 – Host cell interaction and immune response	
Room	1-3	
Chairs	Sebastian Wurster (Houston, TX/US), Natalie Nieuwenhuizen (Würzburg/DE)	
11:45	S10-01 Immune response of Mucormycosis and perspective for future vaccines Amanda Ribeiro dos Santos (São Paulo/BR)	
12:05	S10-02 Anakinra silences the immune chaos that drives influenza-associated pulmonary aspergillosis <u>Laura Seldeslachts</u> , Sirima Kraisin (Leuven/BE), Intan Dewi (Nijmegen/NL), Simon Feys, Frederik Staels (Leuven/BE), Marina Gkountzinopoulou (Heraklion/GR), Cato Jacobs, Birger Tielemans, Eliane Vanhoffelen, Agustin Reséndiz-Sharpe, Lander De Herdt, Oswin Kwan, Niels Vandamme, Jana Roels, Julika Neumann, Teresa Prezzemolo (Leuven/BE), Bert Malengier-Devlies (Edinburgh/GB), Mathias Stroobants (Leuven/BE), Agostinho Carvalho (Braga/PT), Patrick Matthys, Lieve Naesens, Katrien Lagrou (Leuven/BE), Mona Khan, Peter Mombaerts (Frankfurt a. M./DE), Erik Verbeken, Kimberly Martinod, Joost Wauters (Leuven/BE), Frank van de Veerdonk (Nijmegen/NL), Greetje Vande Velde, Stephanie Humblet-Baron (Leuven/BE)	
12:20	S10-03 Characterization of programmed cell death in <i>Aspergillus fumigatus</i> conidia to enable the design of a ‘live/dead’ reporter strain <u>Melanie Händel</u> , Katherine Gonzalez Rojas, Moemi Kawashima, Thomas Krüger, Sascha Schäuble, Thorsten Heinekamp, Axel A. Brakhage (Jena/DE)	
12:32	S10-04 Host cell-derived extracellular vesicles interact with <i>Aspergillus fumigatus</i> <u>Corissa Visser</u> , Maximilian Knott, Zoltán Cseresnyés, Marc-Thilo Figge, Matthew Blango, Axel A. Brakhage (Jena/DE)	
12:44	S10-05 Active Immunization against mucormycosis, first preclinical evidence Kai Dallmeier (Leuven/BE)	



11:45–13:00 Session 11 – Epidemiology and resistance mechanisms
 Room 4-5
 Chairs Joost Wauters (Leuven/BE), Zoi-Dorothea Pana (Nikosia/CY)

11:45 [S11-01](#)
 Fungal Epidemiology and Resistance
 Alexander Aldejohann (Würzburg/DE)

12:00 [S11-02](#)
 Dual use of antifungals as a hidden driver of global resistance
 Michaela Lackner (Innsbruck/AT)

12:15 [S11-03](#)
 Outcome of invasive *Candida* infections in Europe and the US: results from an ongoing multinational study [2024-2026]
[Laman Rahimli](#), Nijat Azimli, Natalia Vasenda, Jon Salmanton-García, Rosanne Sprute (Köln/DE), Iker Falces-Romero, Maricela Valerio Minero, Ana Soriano, Andrea Gutierrez Villanueva (Madrid/ES), Patricia Monzo-Gallo, Carolina Garcia-Vidal (Barcelona/ES), Frank Hanses (Regensburg/DE), Jose Vazquez, Patrick Yu (Augusta, GA/US), Ulrike Scharmann (Essen/DE), Oliver A. Cornely, Danila Seidel (Köln/DE)

12:25 [S11-04](#)
 Epidemiology of human histoplasmosis cases in Germany in the years 2023 and 2024
 Sebastian Reusch, Sina Ackermann, Jasmin Gerkrath, Tobias Woelki, Volker Rickerts (Berlin/DE)

12:35 [S11-05](#)
 Trends of azole-resistant *Aspergillus fumigatus* susceptibility over 12 years from a German ECMM Excellence center
[Hedda L. Verhasselt](#), Lara Thissen, Ulrike Scharmann, Silke Dittmer, Peter-Michael Rath (Essen/DE), Jörg Steinmann (Nürnberg/DE), Lisa Kirchhoff (Essen/DE)

12:45

[S11-06](#)

Human Coccidioidomycosis in Germany (2011-2023): Molecular epidemiology and *in vitro* resistance

[Mandy Messal](#), [Theresa Störko](#), Jana Michel, Jasmin Gerkrath, Sina Ackermann, Simon H. Tausch, Volker Rickerts (Berlin/DE)

12:55

[S11-07](#)

Domestic bathrooms as reservoirs for eye-infecting *Fusarium* species

[Enrico Garbe](#), Ahsan Ullah, Umer Farooq, Alexandra Gille, Slavica Janevska, Grit Walther (Jena/DE)

13:00–13:15

[Closing Ceremony](#)

Room

1-3



Thank you!

25
years

conventus

CONGRESSMANAGEMENT





- 17:15–18:45 **Poster session I**
Room Foyer (Upper floor)
- 17:15 **LTP-01**
Comparison of two Commercial Realtime PCR Assays for the Detection of *Aspergillus*-DNA
Dirk Schmidt, Hedda L. Verhasselt, Laura-Isabel Korth, Andrea Hain, Jan Buer, Peter-Michael Rath (Essen/DE)
- 17:18 **LTP-02**
A PCR-based approach for the detection of dermatophytes: Insights from real-life clinical data
Stephan Steixner, Stefan Fuchs, Roya Vahedi-Shahandashti, Cornelia Lass-Flörl (Innsbruck/AT)
- 17:21 **LTP-03**
NFDI4Microbiota supporting microbiology research providing data access, services, training and workflows
Lina Junctorius, Konrad U. Förstner (Köln/DE), Alice C. McHardy (Braunschweig/DE)
- 17:24 **LTP-04**
Elucidating the contribution of Ugp1 in *Aspergillus fumigatus* 5-fluorocytosine activity
Lukas Birštonas, Fabio Gsaller, Alexander Kühbacher (Innsbruck/AT)
- 17:27 **LTP-05**
Antifungal tolerance – the ability of fungi to make therapy difficult
Katarzyna Góralska, Małgorzata Szybka, Filip Karuga, Dorota Pastuszek-Lewandoska, Ewa Brzezińska-Lasota (Łódź/PL)
- 17:30 **LTP-06**
Detecting tolerance in *non-albicans Candida* species from blood culture – a pilot for the ECMM-Candida IV study
Katharina Rosam, Roya Vahedi-Shahandashti (Innsbruck/AT), Stella Wolfgruber (Graz/AT), Oliver A. Cornely (Köln/DE), Martin Hönigl (Graz/AT), Cornelia Lass-Flörl (Innsbruck/AT)
- 17:33 **LTP-07**
Employing human *in vitro* macrophage models to identify early immune response mediators against *Aspergillus fumigatus*
Jeany Söhnlein (Würzburg/DE), Sascha Schäuble (Jena/DE), Zahraa Abboud (Würzburg/DE), Kerstin Hünninger-Ast (Jena/DE), Michelle Seif, Hermann Einsele, Andreas Beilhack, Jürgen Löffler (Würzburg/DE)

- 17:36 **LTP-08**
Responses of human monocytes to co-infection with *Candida albicans* and *Staphylococcus aureus*
Gabriel Braune, Natalie Nieuwenhuizen (Würzburg/DE),
Kerstin Hünninger-Ast (Jena/DE), Knut Ohlsen (Würzburg/DE),
Oliver Kurzai (Würzburg, Jena/DE)
- 17:39 **LTP-09**
Intracellular survival of *Lichtheimia corymbifera* in macrophages
Rasha Zaher, Franziska Schmidt, Thorsten Heinekamp, Axel A. Brakhage (Jena/DE)
- 17:42 **LTP-11**
Establishment of a molecular system to assess RNA-DNA triple helix formation in *Aspergillus fumigatus*
Valentina Lazarova, Laura Fabre, Akanksha Mourya, Amelia E. Barber,
Holger Bierhoff, Matthew Blango (Jena/DE)
- 17:45 **LTP-12**
Cytostatic drugs against Pancreatic Ductal Adenocarcinoma (PDAC) can cross-affect the viability of the pro-carcinogenic yeast *Malassezia globosa*
Sophie Mühlmann, Fabienne Nocera, Arno Amann, Manuel Maglione,
Nadia Parth, Cornelia Speth, Günter Rambach (Innsbruck/AT)
- 17:48 **LTP-13**
Diversity of pathogenic *Fusarium* species in outdoor environment
Leif Lammers, Grit Walther, Enrico Garbe, Slavica Janevska (Jena/DE)
- 17:51 **PI-01**
qPCR-based molecular detection of *Trichophyton indotineae* by targeting divergent sequences
Engin Kaplan (Istanbul/TR), Oğuzhan Bingöl (Sarıçam, Adana/TR),
Hazal Kandemir (Utrecht/NL), Ayşe Sultan Karakoyun (Sarıçam, Adana/TR),
Murat Durdu (Adana/TR), Macit Ilkit (Sarıçam, Adana/TR)
- 17:56 **PI-02**
Acute invasive fungal Rhinosinusitis in immunocompromised patients:
How seminested PCR helps bridge the gap between clinical suspicion and fungal identification
Nesma Ahmed (Alexandria/EG)

- 18:01 **PI-03**
Candida species culture positivity in patients with indwelling urinary catheters: the potpourri of white aggregates and inconsistent CFU counting
 Stephan Steixner, Angelika Bauer, Rosa Bellmann-Weiler, Cornelia Lass-Flörl (Innsbruck/AT)
- 18:06 **PI-04**
 Terbinafine-resistant *Trichophyton indotineae* infection: A case report
 Valentina L. Müller, Milan Vidakovic (Duisburg/DE), Silke Uhrlaß, Pietro Nenoff (Rötha OT Mölbis/DE), Alexander Kreuter (Duisburg/DE)
- 18:11 **PI-05**
 Neurotropic fungal infection caused by *Cladophialophora bantiana*: Novel insights into antifungal susceptibility and genomic characterization
Kathrin Spettel, Felix Lötsch, Richard Kriz, Florian Thalhammer, Sarah Frank, Majda Thurnher, Birgit Willinger (Wien/AT)
- 18:16 **PI-06**
Trichophyton quinckeanum: Renaissance of a dermatophyte in Germany
 Christin Pelzer (St. Gallen/CH), Pietro Nenoff, Daniela Koch, Hanna Muetze, Constanze Krueger (Rötha OT Mölbis/DE), Antonio Cozzio (St. Gallen/CH), Silke Uhrlaß (Rötha OT Mölbis/DE)
- 18:21 **PI-07**
 Current practices and challenges in antifungal stewardship for hematological malignancy patients
Jon Salmanton-García (Köln/DE), Eleni Gavrilaki, Paschalis Evangelidis, Nikolaos Kotsiou, Ioanna Sakellari (Thessaloniki/GR), Livio Pagano (Rom/IT), Oliver A. Cornely (Köln/DE)
- 18:26 **PI-08**
 Co-treatment with transporter inhibitors distinctly reduces inhibitory concentration levels of itraconazole in azole resistant *Trichophyton indotineae* isolates
 Anna Günther, Anke Burmester, Jörg Tittelbach, Mario Fabri, Cornelia Wiegand (Jena/DE)

12:15–13:30 Poster session II

Room Foyer (Upper floor)

12:15 PII-01

Presence of *Trichophyton tonsurans* between 2008 and 2024 in Germany
Ganna Devdera (Siegen/DE), Silke Uhrlaß, Zora Herrmann, Daniela Koch,
Hanna Muetze, Constanze Krueger, Pietro Nenoff (Rötha OT Mölbis/DE)

12:20 PII-02

Clinical insights into invasive Aspergillosis among immunosuppressed patients:
a single-centre experience from Argentina
Jon Salmanton-García (Köln/DE), Julieta Carballo, Carlos Bergallo,
Federico Romero, Belén Palacio, Lizet Luque-Aguada, Marcos Marino,
Fernando Riera (Córdoba/AR)

12:25 PII-03

DBRMC – A novel database for resistance mutations in *Candida*
Richard Kriz, Kathrin Spettel, Sonia Galazka, Nina Schweitzer,
Alexandra Graf, Birgit Willinger (Wien/AT)

12:30 PII-04

Invasive fungal infections in B-cell lymphoma
Shyam Krishnan, Natia Inadze, Ketema A. Merga, Sarah Vielreicher,
Sabine M. Peter, Christian Kosan, Ilse D. Jacobsen (Jena/DE)

12:35 PII-05

The effect of lung colonisation with *Candida albicans* on *Staphylococcus aureus* infection
Tobias Köhler, Natalie Nieuwenhuizen, Eslam Ibrahim (Würzburg/DE),
Ilse D. Jacobsen (Jena/DE), Tobias Hertlein, Maria Batliner (Würzburg/DE),
Wibke Böhnke (Jena/DE), Annika Schöninger, Knut Ohlsen (Würzburg/DE),
Oliver Kurzai (Würzburg, Jena/DE)

12:40 PII-06

Victory in battle, defeat in war: Navigating isavuconazole implementation at an
Argentinian tertiary centre
Jon Salmanton-García (Köln/DE), Carla Niveyro, Pedro-Andrés Villalba-Apestegui,
Victoria-Isabel Martín, Lucila Compañy-Kec, Vanesa-Eugenia Sosa,
Gustavo A. Méndez (Posadas/AR)

12:45 PII-07

Green synthesis, characterization and antimicrobial potential of silver
nanoparticles from the mushroom *Ganoderma oregonense*
Lauretta Ofodile, Osarume Victor, Omalabake Asulewon (Lagos/NG)

- 12:50 **PII-08**
Correlation of bifonazole uptake in Bovine Hoof Sheet with *in vitro* antifungal efficacy for improved onychomycosis treatment formulations
Udo Bock (Tawern/DE), Anna L. Nellesen, Sebastian Kappes (Bonn/DE), Christiane Kolb (Leverkusen/DE), Silke Uhrlaß, Pietro Nenoff (Rötha/DE), Alf Lamprecht (Bonn/DE)
- 12:55 **PII-09**
Spread of *Trichophyton indotineae* (*Trichophyton mentagrophytes* ITS genotype VIII) after 6 years of data analysis in Germany
Silke Uhrlaß, Daniela Koch, Hanna Muetze, Constanze Krueger, Pietro Nenoff (Rötha OT Mölbis/DE)
- 13:00 **PII-10**
The nutritional environment during sporulation alters fitness of *Aspergillus fumigatus* conidia
Delara Soltan Esmaili, Johannes Berges, Sven Krappmann, Heiko Bruns (Erlangen/DE)
- 13:05 **PII-11**
ImmunoPET and LSM-based imaging for early diagnosis of invasive Aspergillosis using Fc-modified anti-*Aspergillus fumigatus* antibodies
Sophie Tonneau (Tübingen/DE), Lea Allerchen (Essen/DE)
- 13:10 **PII-12**
Clinical insights into Mucormycosis among immunosuppressed patients: a multicentre experience from Argentina
Jon Salmanton-García (Köln/DE), Carla Niveyro (Posadas, Misiones/AR), Vanesa-Eugenia Sosa (Misiones/AR), Verónica Arce (Chaco/AR), María Agustina Aguirre (Formosa/AR), Pedro-Andrés Villalba-Apestegui (Posadas/AR), Victoria-Isabel Martín, Lucila Compañy-Kec (Posadas, Misiones/AR), María Cynthia Tomasino, Ricardo Solari (Posadas/AR), Fernando Ramón Achinelli (Corrientes/AR), Kevin Nguyen, Oliver A. Cornely, (Köln/DE), Gustavo A. Méndez (Posadas, Misiones/AR)
- 13:15 **PII-13**
Fusarium keratoplasticum displays a high virulence potential in a 3D cornea infection model
Annika Schöninger, Anna Zimmermann (Würzburg/DE), Grit Walther (Jena/DE), Oliver Kurzai (Würzburg, Jena/DE), Ronny Martin (Würzburg/DE)

13:20

PII-14

Image processing algorithms to differentiate the extent of *in vitro* infections with *T. rubrum* on bovine hoof sheets

Udo Bock (Tawern/DE), Dirk Neumann (Kleinblittersdorf/DE)

13:25

PII-15

Activin A in the response to *Candida albicans* infection

Natalie Nieuwenhuizen (Würzburg/DE), Rosanne Sprute (Köln/DE), Gabriel Braune, Jennifer Patitz (Würzburg/DE), Aia Shehata, Kerstin Hünninger-Ast (Würzburg, Jena/DE), Oliver A. Cornely (Köln/DE)





Registration

Please register online at www.dmykg-kongress.de. There you will find all information on conference fees, payment of fees and payment confirmations as well as the General Terms and Conditions.



Conference language

The conference languages are German and English.



Name badges

Access to the conference and the industrial exhibition is only possible with a name badge. You will receive this at the check-in desk.



Certification

The MYK 2025 is recognised by the **Medical Association North Rhine** as follows.

4 September – Category A | 3 Points

5 September – Category A | 4 Points

6 September – Category A | 4 Points

The MYK 2025 is approved by the **Academy for Advanced Veterinary Training** as follows.

4 September – 5 hours

5 September – 7 hours

6 September – 4 hours



Publication of abstracts

The abstract book for the conference will be published online on the conference homepage at www.dmykg-kongress.de.



Photo competition

There will again be a photo competition at MYK 2025 with photos submitted by participants. All information and the opportunity to submit photos can be found on the conference website www.dmykg-kongress.de.



Catering

During breaks, a small selection of fruit and snacks as well as coffee and tea will be available. Lunch can be purchased at your own expense in the surrounding restaurants and cafés. Water stations are available at the venue. For environmental reasons, please bring refillable water bottles with you.



Poster sessions

Please note: The posters will not be exhibited for the entire conference. In Poster session I, the posters for the Lightning Talks will be presented. Authors are requested to hang their posters by 12:00 on 4 September and remove them by 9:00 on Friday, 5 September at the latest. Authors of Poster session II are requested to hang their posters by 9:30 on Friday morning, 5 September, and remove them by 16:00 on the same day. No posters will be kept or forwarded.

Please produce your poster in A0 format (84.1 cm x 118.9 cm, portrait format). Fixing material is provided on the poster wall, which will be labelled with your poster number. The poster prizes will be awarded at the social evening.



Speaking times for talks

Please prepare your talk in such a way that the allocated time, which includes the discussion, is maintained. The chairs are required to ensure that the speaking time is adhered to.



Technical information

Please prepare your presentation in aspect ratio 16:9. PDF and PowerPoint are accepted. The use of different versions during the submission of presentations could lead to formatting issues. Please note that the corresponding CODEC for the playback of video sequences must be provided by yourself. Corresponding technical equipment will be provided on site.

There will be no central media check-in. Presentations will be received directly in the respective lecture hall. Please bring your presentation file to the congress on a mobile storage medium, ideally on a USB drive. The use of your own computer for your presentation is not necessary and not intended.



Prizes of the Foundation of the German speaking Mycological Society e. V.

Publication Prize of the DMykG Foundation | Publikationspreis der DMykG-Stiftung

The DMykG e. V. Foundation awards prizes for excellent scientific publications in the fields of medical and veterinary mycology. The prizes are funded with EUR 1,000.00 each.

Poster prizes of the DMykG Foundation | Posterpreise der DMykG-Stiftung

The foundation awards three poster prizes for excellent scientific work, which can cover the whole spectrum of DMykG research work. In addition, the Hans Rieth Poster Prize is awarded for the special didactic design of a scientifically excellent poster. The poster prizes are worth EUR 250 each.

These prizes will be awarded during the social evening.



Prizes of the German speaking Mycological Society e. V. Research Award | Forschungsförderpreis

The DMykG awards the Research Promotion Prize (funding: EUR 5,000) to members who have made excellent, internationally recognised achievements in the areas of clinical or experimental research in the field of medical mycology. The award winner should be expected to make significant scientific achievements in their future career.

The research award will be awarded during the opening ceremony.

Schönlein Plaque | Schönlein-Plakette

The Johann-Lucas-Schönlein-Plaque, donated by the DMykG e.V., is awarded to natural persons who have rendered outstanding services to the cause of mycology in the spirit of the society. The plaque is awarded during the social evening.

Photo competition

The three best photos in the competition will be selected by the participants. The awards ceremony (the first prize is endowed with EUR 500, the second and third prizes with EUR 250 each) will take place during the social evening.



SOCIAL PROGRAMME

Welcome reception

Come together over drinks and snacks and enjoy the first evening of the congress in a very pleasant atmosphere. Get in the mood for MYK 2025 at the welcome reception in the industrial exhibition. Have interesting conversations with colleagues, old friends and meet new acquaintances.

Date	Thursday, 4 September
Time	18:30–20:00
Place	Foyer (Ground floor) / Industrial exhibition
Costs	free of charge for congress participants (registration is required) Accompanying persons EUR 10

Social evening

Celebrate the end of the second day of the congress at the Stapelhaus in Cologne, review what you have experienced so far and enjoy an entertaining evening with good food, music and interesting discussions.

Date	Friday, 5 September
Time	19:30–23:00 (Entry from 19:00)
Place	Stapelhaus Köln Frankenwerft 35 50667 Köln
Costs	EUR 75 Participants/accompanying persons EUR 50 Students

We would like to sincerely thank the following companies for their kind support:

Sponsors

Basilea Pharmaceutica International Ltd.



Gilead Sciences GmbH



Mundipharma Deutschland GmbH & Co KG



Pfizer Pharma GmbH



Shionogi GmbH



Further supporting companies

Pulmocide Ltd



SCYNEXIS, Inc. (SCYX)



Cologne Convention Bureau



Exhibitors

Associates of Cape Cod, Inc.

EUROIMMUN Medizinische Labordiagnostika AG

FUJIFILM Wako Chemicals Europe GmbH

GILEAD Sciences GmbH

Pfizer Pharma GmbH

Shionogi GmbH

TECOMedical AG

Xpedite Diagnostics GmbH

Disclosure

In accordance with the guidelines of the FSA Code, the support services provided by members of the Voluntary Self-Regulation of Pharmaceutical Companies (FSA) are disclosed, including on the official conference website www.dmykg-kongress.de: Associates of Cape Cod Europe GmbH EUR 1,400 | Basilea Pharmaceutica International Ltd. – EUR 15,000 | EUROIMMUN Medizinische Labordiagnostika AG – EUR 2,100 | FUJIFILM Wako Chemicals Europe GmbH – EUR 1,400 | GILEAD Sciences GmbH – EUR 15,000 | Mundipharma Deutschland GmbH & Co KG – EUR 16,300 | Pfizer Pharma GmbH – EUR 12,500 | Pulmocide Ltd - EUR 5,000 Scynexis, Inc. – EUR 1,720 | Shionogi GmbH - EUR 10,000 | TECOMedical AG – EUR 2,100 Xpedite Diagnostics GmbH – EUR 1,400

State at printing

AI Academy



Live Webinare
On-demand Webinare
Studien
CME-Module
Podcasts



[www.pfizerpro.de/
AI-Academy](http://www.pfizerpro.de/AI-Academy)



DIE **INNOVATIVE** PFIZER
FORTBILDUNGSPLATTFORM
IN DER **INFEKTIOLOGIE**

We would like to thank the following media partner for their support:

Trillium Diagnostik
Zeitschrift für interdisziplinäre Medizin



60th Scientific Conference of
the German speaking
Mycological Society (DMykG) e. V.
together with
Austrian Society for Medical Mycology

Myk2026

17–19 September | Graz
www.dmykg-kongress.de

15:15–16:15 Industrial Symposium I – Gilead Sciences GmbH

Kontroversen in der Antimykotikatherapie



Room

1-3

15:15

Welcome note and introduction

Dominic Wichmann (Hamburg/DE)

15:16

Aspergillusdiagnostik aus BL versus BAL?

Dominic Wichmann (Hamburg/DE)

15:34

Antimykotika bei Schimmelpilzinfektionen- Real World Data versus Leitlinien?

Tobias Liebrechts (Essen/DE)

15:52

Discussion

15:54

Antimykotika bei Hefepilzinfektionen – Vertrauen ist gut, Kontrolle ist besser?

Rainer Höhl (Nürnberg/DE)

16:12

Discussion

08:30–09:30 **Industrial Symposium II – Shionogi GmbH**



Invasive Pilzinfektionen heute und morgen:
Herausforderungen und Ausblick

Room 1-3

Vorsitz Oliver A. Cornely (Köln/DE)

08:30 Pilzinfektionen im Wandel – Epidemiologische Einblicke und klinische Lücken
Cornelia Lass-Flörl (Innsbruck/AT)

09:00 Von der Forschung zur Klinik: Neues aus der Antimykotika-Entwicklung
Oliver Kurzai (Würzburg, Jena/DE)

Shionogi invites you to their morning symposium and provides snacks for all participants of the symposium.

11:15–12:15 **Industrial Symposium III – Pfizer Pharma GmbH**



Invasive Mykosen in der Pädiatrie: Aktuelle Entwicklungen
und praktische Herausforderungen

Room 1-3

11:15 Epidemiologie und Herausforderung bzgl. der Diagnostik invasiver Schimmelpilzinfektionen
Thomas Lehrnbecher (Frankfurt a. M./DE)

11:45 Therapieoptionen bei invasiven Schimmelpilzinfektionen in der Pädiatrie
Katrin Mehler (Köln/DE)

Pfizer invites you to their lunch symposium and provides lunch for all participants of the symposium.

15:45–16:45 **Industrial Symposium IV – Mundipharma Deutschland GmbH & Co. KG**



Update Candida: State of the Art, Praxisfälle und Therapieoptionen

Room 1-3

15:45 Herausforderungen bei Candida-Infektionen
Alexander Aldejohann (Würzburg/DE)


16:05 Aktuelle Fälle auf der Intensivstation
Christian Eckmann (Hann. Münden/DE)

16:25 Invasive Candidiasis: Behandlung komplexer Fälle von der Intensivstation in die Ambulanz
Jannik Stemler (Köln/DE)


09:00-10:00	Industrial Symposium V – Basilea Pharmaceutica Ltd, Allschwil Challenges in invasive mold and yeast infections – drugs in development, impact on guidelines and meeting the unmet medical need Room 1-3	
09:00	Todays challenges in treating invasive fungal diseases and drugs in development Werner Heinz (Bad Mergentheim/DE)	
09:17	Potential impact of new agents on every day clinical decision making and stewardship – considerations for future Candida treatment guidelines Oliver A. Cornely (Köln/DE)	
09:34	Fosmanogepix, a first in class gepix antifungal – update on clinical program and experience from the Expanded Access Program Marc Engelhardt (Allschwil/CH)	
09:51	Audience discussion with the Speaker panel	



Foyer (Ground floor)



Foyer (Upper floor)





A

A. Ahmed, S.	27	Brakhage, A. A.	15, 16, 18, 24, 25, 28, 33
A. I. Ismail, M.	27	Brasch, J.	21
Abboud, Z.	18, 33	Braune, G.	18, 33, 37
Achinelli, F. R.	36	Brill, F. H. H.	20, 27
Ackermann, S.	29, 30	Bruns, H.	36
Aebischer, A.	16	Brzeziańska-Lasota, E.	18, 32
Aguirre, M. A.	36	Buchberger, B.	15
Ahmed, N.	34	Buer, J.	17, 32
Aimanianda, V.	16	Burmester, A.	22, 34
Aldejohann, A.	12, 29, 47	Butler, G.	27
Alex, J.	25	Butzer, S.	7, 19
Allerchen, L.	21, 36		
Altay, L.	21		
Aly, D.	24		
Amann, A.	19, 33		
Apostolopoulou, A.	20		
Arce, V.	36		
Asulewon, O.	35		
Azimli, N.	29		

B

Bachelot, Y.	24		
Baldauf, C.	22		
Balogh, L.	27		
Barber, A. E.	19, 27, 33		
Batliner, M.	35		
Bauer, A.	34		
Beilhack, A.	18, 32		
Bellmann-Weiler, R.	34		
Bellotti, R.	27		
Bergallo, C.	35		
Berges, J.	36		
Bierhoff, H.	19, 33		
Bihlmaier, K.	20		
Bingöl, O.	33		
Birštonas, L.	18, 32		
Biswas, S. K.	13, 15, 26		
Blango, M.	19, 24, 27, 28, 33		
Bochennek, K.	19		
Bock, U.	21, 36, 37		
Bogdan, C.	20		
Böhnke, W.	35		

C

Carballo, J.	35
Carvalho, A.	28
Chakrabarti, A.	8, 12, 15
Chakraborti, S.	27
Cömert, D. N.	16
Compañy-Kec	35, 36
Cornely, O. A.	7, 9, 15, 17, 18, 20, 21, 25 26, 29, 32, 34, 36, 37, 47, 48
Cozzi, J. A.	20
Cozzio, A.	34
Cseresnyés, Z.	25, 28
Cursiefen, C.	21

D

Dallmeier, K.	13, 28
De Herdt, L.	28
de Hoog, S.	22, 27
Deeren, D.	20
Denning, D.	7, 12, 25, 26
Devdera, G.	35
Dewi, I.	28
Dichtl, K.	20
Dietz, S.	16
Dittmer, S.	29
Draenert, R.	20
Dumann, K.	22
Durdu, M.	33

E

Egger, M.
Einsele, H.
Erben, N.
Evangelidis, P.

20
18, 32
20
34

F

Fabre, L.
Fabri, M.
Falces-Romero, I.
Farooq, U.
Fauth, T.
Feng, P.
Feys, S.
Figge, M.-T.
Fleischer, V.
Fontaine, T.
Förstner, K. U.
Frank, S.
Frenzel, L.
Fuchs, S.

19, 33
22, 34
20, 29
30
17
22
28
24, 25, 28
17
16
18, 32
34
17
17, 32

G

Gabriel, H.
Galazka, S.
Gangapurwala, G.
Gangneux, J.-P.
Garbe, E.
Garcia-Vidal, C.
Garg, V.
Garred, P.
Gavriilaki, E.
Gerkrath, J.
Giacinta, A.
Giacobbe, D. R.
Giannella, M.
Gille, A.
Gkoutzinopoulou, M.
Glatz, U.
Gonzalez, K.
Gonzalez Rojas, K.
Góralaska, K.
Gorzellany, C.

26
35
25
7, 12, 26
19, 30, 33
29
22
17
34
22, 29, 30
26
12, 16, 24
26
30
28
20
25
28
18, 32
23

Graf, A.
Graf, J.
Gräser, Y.
Gresnigt, M.
Groll, A.
Gsaller, F.
Guerrero-Sánchez, C.
Günther, A.
Gutierrez Villanueva, A.

35
21, 22
22
13, 23
7, 19, 20
18, 32
25
34
29

H

Hagen, F.
Hain, A.
Hallek, M.
Händel, M.
Hanses, F.
Harpf, V.
Häupl, B.
Heger, R.
Heinekamp, T.
Heineking, I.
Held, J.
Herbst, L.
Herrmann, Z.
Hertlein, T.
Hirschsteiner, O.
Hoellinger, B.
Hoeppener, S.
Hönigl, M.
Houbraken, J.
Humblet-Baron, S.
Hünninger-Ast, K.

8, 21
17, 32
17
25, 28
29
17
24
17
15, 18, 25, 28, 33
15, 24
20
20
35
35
22
20
25
7, 18, 20, 32
21
28
16, 18, 24, 32, 33, 37

I

Ibrahim, E.
Ibrahim-Bacha, J.
Ilkit, M.
Imelmann, C.
Inadze, N.
Ishikawa, H.

35
16
33
23
35
24

J

Jacobs, C.	28
Jacobsen, I. D.	7, 15, 23, 27, 35
Janevska, S.	19, 30, 33
Jenks, J. D.	20
Jia, L.	24
Joisten, C.	17, 20
Junctorius, L.	18, 32

K

Kandemir, H.	33
Kang, Y.	27
Kaplan, E.	33
Kappes, S.	36
Karakoyun, A. S.	33
Karuga, F.	18, 32
Kawashima, M.	28
Kelani, A.	27
Kessler, H.	20
Khan, M.	28
Kirchhoff, L.	29
Klatt, A.	22
Klotz, C.	16
Kniemeyer, O.	16, 24
Knott, M.	28
Koch, D.	22, 34, 35, 36
Köhler, P.	17, 20, 25
Köhler, T.	35
Kolamunnage-Dona, R.	20
Kolb, C.	36
Korsch, E.	16
Korth, L.-I.	17, 32
Kosan, C.	35
Kotsiou, N.	34
Kraisin, S.	28
Krappmann, S.	7, 15, 36
Krauße, L.	22
Kreuter, A.	34
Kreuzer, K.-A.	17
Krishnan, S.	35
Kriz, R.	26, 34, 35
Krueger, C.	22, 34, 35, 36
Krüger, T.	24

Kühbacher, A.	18, 32
Kurza, O.	7, 10, 13, 16, 18, 23
	24, 27, 33, 35, 36, 47
Kwan, O.	28

L

Lackner, M.	7, 13, 21, 29
Lagrou, K.	28
Lammers, L.	19, 33
Lamprecht, A.	36
Lang, A.	26
Lass-Flörl, C.	7, 17, 18, 20, 25, 32, 34, 47
Lazarova, V.	19, 33
Lehrnbecher, T.	7, 19, 47
Lentzsch, A.	21
Liss, B.	7, 25
Löffler, J.	18, 32
Lopes Colombo, A.	12, 20
López Soria, L.	20
Lötsch, F.	26, 34
Loy, M.	26
Luque-Aguada, L.	35

M

Macha, K.	20
Maglione, M.	19, 24, 27, 33
Malengier-Devlies, B.	28
Makcevic, E.	21
Maquera-Afaray, J.	20
Marino, M.	35
Martin, R.	27, 36
Martín, V.-I.	35, 36
Martinod, K.	28
Matthys, P.	28
Mayer, U.	22
Mc Cormick Smith, I.	22
McHardy, A. C.	18, 32
Meintker, L.	20
Meis, J.	7, 23, 26
Meister, T. L.	26
Mellinghoff, S.	17
Méndez, G. A.	20, 35, 36

Merga, K. A.	27, 35	Parth, N.	19, 24, 33
Messal, M.	30	Pastuszak-Lewandoska, D.	18, 32
Meyer, A.	16	Patitz, J.	24, 37
Michel, J.	30	Pelzer, C.	34
Mohd-Tap, R.	21	Pereira Brunelli, J. G.	21
Mombaerts, P.	28	Peter, S. M.	35
Monzo-Gallo, P.	29	Picardi, S.	25
Mourya, A.	19, 33	Prattes, J.	20, 27
Muetze, H.	22, 34, 35, 36	Prezzemolo, T.	28
Mühlmann, S.	19, 33		
Müller, C.	17	R	
Müller, V. L.	34	Rahimli, L.	29
Müller-Ohrem, C.	17	Rambach, G.	17, 19, 24, 27, 33
Muñoz, P.	26	Ranches, G.	27
N		Rath, P.-M.	17, 29, 32
Naesens, L.	28	Reinhold, I.	7, 21, 25
Nellessen, A. L.	36	Reséndiz-Sharpe, A.	28
Nemeth, T.	27	Reusch, S.	16, 29
Nenoff, P.	22, 34, 35, 36	Ribeiro dos Santos, A.	12, 15, 28
Neumann, D.	21, 37	Richter, D.	20
Neumann, J.	28	Rickerts, V.	15, 16, 21, 22, 29, 30
Neurauter, M.	24	Riera, F.	35
Nguyen, K.	36	Roels, J.	28
Nieuwenhuizen, N.	18, 24, 28, 33, 35, 37	Roesner, N.	25
Ning, Y.	27	Romero, F.	35
Niveyro, C.	35, 36	Rosam, K.	18, 32
Nocera, F.	19, 33	Rosbjerg, A.	17
O		Rosin, M.	25
O. Abd Algaffar, S.	27	Rudolph, H.	24
Obser, T.	23	Rudramurthy, S.	13, 16
Ofodile, L.	35	Rügamer, T.	7, 20, 25
Ohlsen, K.	18, 33, 35	S	
Orasch, T.	16, 25	Sakellari, I.	34
P		Salmanton-García, J.	7, 21, 26, 29, 34, 35, 36
Paasch, U.	22	Schäfer, G.	27
Pagano, L.	34	Scharmann, U.	29
Palacio, B.	35	Schäuble, S.	18, 28, 32
Pan, X.	27	Schiffer, M.	20
Pana, Z.-D.	13, 19, 29	Schmidt, D.	17, 32
		Schmidt, F.	15, 16, 18, 24, 33
		Schmidt, S.	24

T

Schneider, R.	20	Tang, Y.	27
Scholz, P.	17	Tausch, S. H.	22, 30
Schöninger, A.	35, 36	Thalhammer, F.	34
Schroten, H.	24	Thissen, L.	29
Schubert, U. S.	25	Thurner, G.	27
Schweitzer, N.	35	Thurnher, M.	34
Schwerk, C.	24	Tielemans, B.	28
Schwister, C.	16	Tittelbach, J.	22, 34
Sedik, S.	20	Többen, C.	20
Seidel, D.	7, 9, 10, 15, 17, 20, 25, 29	Tobias, W.	22
Seif, M.	18, 32	Tomasino, M. C.	36
Seldeslachts, L.	23, 28	Tonneau, S.	21, 36
Seyedmousavi, A.	12, 16		
Shehata, A.	16, 37		

U

Skjødt, M.-O.	17	Uhrlaß, S.	7, 21, 22, 34, 35, 36
Söhnlein, J.	18, 33	Ullah, A.	30
Solari, R.	36	Ullmann, MdB, A. J.	16
Söller, R.	22	Uribe Munoz, A.	27

V

Solomatina, A.	24		
Soltan Esmaeili, D.	36		
Soriano, A.	29	Vahedi-Shahandashti, R.	17, 18, 32
Sosa, V.-E.	35, 36	Valerio Minero, M.	13, 24, 27, 29
Speth, C.	7, 17, 19, 24, 27, 33	van de Sande, W.	21
Spettel, K.	26, 34, 35	van de Veerdonk, F.	28
Sprute, R.	7, 9, 10, 15, 17, 21, 25, 29, 37	van der Lee, H.	27
Staels, F.	28	Vandamme, N.	28
Staudenmeyer, J. B.	23	Vande Velde, G.	28
Steinmann, E.	26	Vanhoffelen, E.	28
Steinmann, J.	7, 12, 26, 28, 29	Vasenda, N.	29
Steixner, S.	17, 32, 34	Vazquez, J.	29
Stemler, J.	7, 17, 20, 25, 47	Vena, A.	26
Störiko, T.	22, 30	Verbeken, E.	28
Strauß, R.	20	Verhasselt, H. L.	17, 29, 32
Stroobants, M.	28	Victor, O.	35
Suntz, M.	22	Vidakovic, M.	34
Szybka, M.	18, 32	Vidal-y-Sy, S.	23
		Vielreicher, S.	35
		Villalba-Apestegui, P.-A.	35, 36
		Visser, C.	28
		Vollrath, A.	25
		Vonbrunn, L.	20

W

Walther, G.	19, 27, 30, 33, 36
Walti, L. N.	24, 26
Wauters, J.	13, 24, 28, 29
Weber, C.	25
Wende, A.	21, 22
Wiegand, C.	22, 34
Willam, C.	20
Willinger, B.	7, 12, 23, 26, 34, 35
Woelki, T.	29
Wolfgruber, S.	18, 32
Wölfler, A.	20
Wurster, S.	7, 13, 16, 28
Würzner, R.	17

Y

Yilmaz Karapinar, D.	20
Yu, P.	29

Z

Zaher, R.	15, 18, 33
Zajic, P.	20
Zhai, B.	27
Zhang, L.	27
Zhou, S.	27
Zhou, X.	22
Zimmermann, A.-K.	24
Zimmermann, A.	36
Zurek, C.	17

Mundipharma-Symposium

„Update Candida: State of the Art, Praxisfälle und Therapieoptionen“

Herausforderungen bei Candida-Infektionen
Dr. Alexander Aldejohann (Würzburg)

Aktuelle Fälle auf der Intensivstation
Prof. Dr. Christian Eckmann (Hann. Münden)

Invasive Candidiasis: Behandlung komplexer Fälle von der Intensivstation in die Ambulanz
Dr. Jannik Stemler (Köln)

Freitag, 05. September
15:45–16:45 Uhr | Raum 1–3

Wir freuen uns auf Sie!

REZZAYO 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung


Wirkstoff: Rezafungin (als Acetat)

Verschreibungspflichtig.

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden.

Zusammensetzung: *Arzneilich wirksamer Bestandteil:* Jede Durchstechflasche enthält 200 mg Rezafungin (als Acetat). *Sonstige Bestandteile:* Mannitol, Histidin, Polysorbat 80, Salzsäure (zur pH-Wert-Einstellung), Natriumhydroxid (zur pH-Wert-Einstellung). **Anwendungsgebiete:** REZZAYO wird angewendet zur Behandlung der invasiven Candidainfektion bei Erwachsenen. Es sind die offiziellen Richtlinien zur sachgemäßen Anwendung von Antimykotika zu beachten. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile, Überempfindlichkeit gegen andere Arzneimittel der Klasse der Echinocandine. **Nebenwirkungen:** Sehr häufig: Anämie; Hypokaliämie; Diarrhoe; Fieber. Häufig: Hypomagnesiämie, Hypophosphatämie; Hypotonie; Giemen; Erbrechen, Übelkeit, Abdominalschmerz, Obstipation; Erythem, Ausschlag; erhöhte alkalische Phosphatase im Blut, erhöhte Leberenzyme, erhöhte Alaninaminotransferase, erhöhte Aspartataminotransferase, erhöhtes Bilirubin im Blut; Infusionsbedingte Reaktionen (wie Rötung, Gefühl der Wärme, Übelkeit und Brustenge). Gelegentlich: Hyperphosphatämie, Hyponatriämie; Phototoxizität; Tremor; erhöhte Eosinophilenzahl. Nicht bekannt: Urtikaria. **Warnhinweis:** Arzneimittel für Kinder unzugänglich aufbewahren. **Mundipharma GmbH, 60549 Frankfurt am Main.**

02-25



25 YEARS
basilea

**Seit 25 Jahren:
Stark in der
Entwicklung
neuer Antiinfektiva**